DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 202288
The generic ingredient in LITHIUM CARBONATE is lithium carbonate. There are fifteen drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the lithium carbonate profile page.
Summary for 202288
Tradename: | LITHIUM CARBONATE |
Applicant: | Mylan Pharms Inc |
Ingredient: | lithium carbonate |
Patents: | 0 |
Therapeutic Class: | Bipolar Agents |
Formulation / Manufacturing: | see details |
Suppliers and Packaging for NDA: 202288
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
LITHIUM CARBONATE | lithium carbonate | TABLET, EXTENDED RELEASE;ORAL | 202288 | ANDA | Mylan Pharmaceuticals Inc. | 0378-1300 | N | 0378-1300-05 |
LITHIUM CARBONATE | lithium carbonate | TABLET, EXTENDED RELEASE;ORAL | 202288 | ANDA | Mylan Pharmaceuticals Inc. | 0378-1300 | N | 0378-1300-01 |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 300MG | ||||
Approval Date: | Jun 29, 2012 | TE: | AB | RLD: | No |
Complete Access Available with Subscription